4 papers in the library · 90 citations · publishing 2011-2024
Australian Journal of Chemistry January 19, 2024 Scott R. Walker, Glenn A. Pullella, Matthew Piggott et al. correction
© 2024 The Author(s) (or their employer(s)). Published by CSIRO Publishing. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)
Australian Journal of Chemistry July 11, 2023 Katie D. Lewis, Glenn A. Pullella, Han Chern Loh et al. 2 citations
Homochiral (R)- and (S)-3,4-methylenedioxymethamphetamine (MDMA) were prepared in six steps (each) from the chiral pool precursors d- and l-alanine, respectively. The key step, copper-catalysed regioselective ring-opening of an N-tosylaziridine with an aryl Grignard reagent, proceeded in high yield with complete regioselectivity. Elaboration was achieved with preservation of configurational...
Australian Journal of Chemistry July 4, 2023 Scott R. Walker, Glenn A. Pullella, Matthew Piggott et al. 5 citations
The science of psychedelics is an intriguing, multi-disciplinary field that has recently been the subject of heightened public interest. This has mainly resulted from publicity associated with a number of high-profile investigations into psychedelic-assisted therapy for a range of difficult-to-treat mental health conditions. With many psychedelic substances known, including natural,...
Journal of Neuroscience May 11, 2011 Philippe Huot, Tom H. Johnston, Katie D. Lewis et al. 83 citations
l -3,4-Dihydroxyphenylalanine ( l -DOPA) is the most effective treatment for Parkinson's disease, but long-term l -DOPA administration is marred by the emergence of motor complications, namely, dyskinesia and a shortening of antiparkinsonian benefit (wearing-OFF). 3,4-Methylenedioxymethamphetamine (MDMA) is unique in that it exerts antidyskinetic effects and may enhance antiparkinsonian actions...